Cheshire Dash

200 Mile Bike Ride in 2 days

The Cheshire Flyers, a friendly and informal group of local cyclists, are looking to recruit 100 cyclists who are up for a big challenge. It’s for an amazing cause, to help end Duchenne Muscular Dystrophy, which is a killer of young boys. The route has been planned for both experienced riders and new but determined riders and will be both beautiful and testing. We’ll ensure all our riders receive VIP treatment and in return they’ll help us to achieve our fundraising target of £100,000.

Can you challenge yourself to cycle 200 miles in 2 days?

When: 7th and 8th July 2018
Where: The Dash will start and finish at Goostrey in the heart of Cheshire
Distance: 200 Miles in 2 days
Fundraising target: £1,000 per cyclist
Registration cost: £100 – this includes overnight accommodation, food on the route, an evening meal, bike support – including mechanics and first aid cover, a jersey, medal and certificate
For Free: that feeling of camaraderie when you’re doing something special as a group to truly make a difference

To register please go to www.eventbee.com/event?eid=101064316
Or, if you’d like further information, please email [email protected]

The organisers have kindly agreed to cover the £100 registration fee for any riders who are Duchenne families, please email [email protected] to claim your place.

Event details

Where

Goostrey

View map

When

Start: 7^th July, 2018 at 10:00am

End: 8^th July, 2018 at 8:00pm

Add to calendar

Latest

Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

We are excited to share the news with the Duchenne community highlighting an important advancement in the Phase 1b, Multicenter, Open-label, Single Ascending Dose Study.
Soy Products Study: Your Questions Answered

Duchenne UK recently posted a publication by Professor Steve Winder investigating a nutraceutical soy project Haelan 951. Following the publication, Duchenne UK have collated some of the questions from the Duchenne community and working with Steve Winder we have answered them.
VISION-DMD Update:

VISION-DMD is an EC funded project undertaking Phase 2 clinical studies on vamorolone, a new treatment for DMD. Vamorolone (also known as VBP15) is a dissociative steroid designed to have the efficacy of a steroid, without the severe associated side effects. The first Phase 2b study site is expected to open for recruitment in April 2018
An update on soy product research funded by Duchenne UK

In August 2016 Duchenne UK commissioned Professor Steve Winder at The University of Sheffield to investigate a nutraceutical soy product called Haelan 951, as a treatment for Duchenne muscular dystrophy. Results of the study published today in PLOS Currents.